Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3814549 | 0.85 | HTR1A (0.32) | CA2 | |
| SCHEMBL3818000 | 0.82 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL3815359 | 0.81 | TLR7 (0.49) | TLR7TLR8 | |
| SCHEMBL3815706 | 0.80 | HTR1A (0.47) | TLR7POLBLMNAHRH2ADRA1D | |
| SCHEMBL3815194 | 0.79 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL3812768 | 0.77 | TLR8 (0.54) | TLR7NUDT1TLR8 | |
| SCHEMBL5370008 | 0.75 | TLR7 (0.60) | TLR7POLBLMNAHRH2ADRA1D | |
| SCHEMBL13914482 | 0.75 | TLR7 (0.57) | TLR7POLBLMNAHRH2ADRA1D | |
| SCHEMBL5358343 | 0.75 | TLR7 (0.59) | TLR7POLBLMNAHRH2ADRA1D | |
| SCHEMBL3858505 | 0.75 | TLR7 (0.56) | TLR7POLBLMNAHRH2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642580-B1 | Sulfonamide substituted imidazoquinolines | COLEY PHARM GROUP INC (US) | 2009-08-19 | — | — | EP | claimed |
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-12 | — | — | US | claimed |
| US-6331539-B1 | INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-12-18 | — | — | US | claimed |
| EP-1642580-B1 | Sulfonamide substituted imidazoquinolines | COLEY PHARM GROUP INC (US) | 2009-08-19 | — | — | EP | disclosed |
| US-7199131-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060106052-A1 | METHOD OF USING SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-18 | — | — | US | disclosed |
| US-7030131-B2 | Sulfonamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2006-04-18 | — | — | US | disclosed |
| EP-1642580-A1 | Sulfonamide substituted imidazoquinolines | 3M Innovative Properties Company (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-6924293-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-6888000-B2 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-03 | — | — | US | disclosed |
| US-6825350-B2 | ADMINISTERING DOSAGE OF IMMUNOLOGY RESPONSE MODERATOR | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-30 | — | — | US | disclosed |
| US-20040204438-A1 | Sulfonamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-6800624-B2 | INDUCE BIOSYNTHESIS OF CYTOKINES; IMMUNE RESPONSE MODIFIERS; TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-12 | — | — | US | disclosed |
| US-6677349-B1 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-6331539-B1 | INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885POLB 3612/4885LMNA 4783/4885 |
| US-20060106052-A1 | METHOD OF USING SULFONAMIDE SUBSTITUTED IMIDAZOQUINOLINES | IFNG, MYD88, IL2 | TLR7 28/4885POLB 2647/4885LMNA 4475/4885 |
| US-20050197358-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885POLB 3612/4885LMNA 4783/4885 |
| US-20040204438-A1 | Sulfonamide substituted imidazoquinolines | IRF3, IFNG, EIF2AK2 | TLR7 37/4885POLB 3790/4885LMNA 4694/4885 |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885POLB 3612/4885LMNA 4783/4885 |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885POLB 3612/4885LMNA 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.